BPTH
Bio-Path Holdings, Inc.
Price Chart
Latest Quote
$0.03
+0.00 (+1.01%)
Current Price
| Previous Close | $0.03 |
| Open | $0.03 |
| Day High | $0.03 |
| Day Low | $0.03 |
| Volume | 323 |
Stock Information
| Shares Outstanding | 50.30M |
| Total Debt | $511K |
| Cash Equivalents | $12K |
| Net Income | $-6.09M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.51M |
| EPS (TTM) | $-1.14 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.01M |
| Income | $-6.09M |
| Book/sh | $-0.91 |
| Cash/sh | $0.00 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.07 |
Returns & Margins
| ROA | -234.51% |
Ownership
| Insider Ownership | 0.00% |
| Institutional Ownership | 0.87% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.01 |
| P/B | -0.03 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.04 |
| SMA50 | $0.05 |
| SMA200 | $0.07 |
| RSI | 42.86 |
| ATR | 0.0121 |
| Shares Float | 49.91M |
| Short Float | 1.38% |
| Short Ratio | 0.43 |
| Volatility | -0.41 |
| Rel Volume | 0.01 |
Performance History
| Week | +0.00% |
| Month | -50.00% |
| Quarter | -50.00% |
| 6 Months | -57.14% |
| YTD | -50.00% |
| Year | -85.00% |
| 3 Years | -99.91% |
| 5 Years | -99.97% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $0.03 | 323 |
| 2026-06-04 | $0.03 | 36,000 |
| 2026-06-03 | $0.03 | 23,700 |
| 2026-06-02 | $0.04 | 6,300 |
| 2026-06-01 | $0.04 | 19,900 |
| 2026-05-29 | $0.03 | 26,400 |
| 2026-05-28 | $0.04 | 70,400 |
| 2026-05-27 | $0.04 | 20,400 |
| 2026-05-26 | $0.04 | 117,100 |
| 2026-05-22 | $0.04 | 102,800 |
| 2026-05-21 | $0.03 | 17,100 |
| 2026-05-20 | $0.03 | 13,300 |
| 2026-05-19 | $0.02 | 52,900 |
| 2026-05-18 | $0.04 | 63,000 |
| 2026-05-15 | $0.04 | 44,600 |
| 2026-05-14 | $0.03 | 56,500 |
| 2026-05-13 | $0.03 | 156,400 |
| 2026-05-12 | $0.04 | 245,900 |
| 2026-05-11 | $0.05 | 106,100 |
| 2026-05-08 | $0.05 | 49,500 |
| 2026-05-07 | $0.06 | 1,000 |
| 2026-05-06 | $0.06 | 28,800 |
| 2026-05-05 | $0.06 | 10,400 |
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
đ° Latest News
No news articles available at the moment. Check back later for updates on BPTH.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $11,992,000 | $15,843,000 | $13,901,000 | $10,443,000 |
| Other Income Expense | $2,084,000 | $-271,000 | - | - |
| Net Non Operating Interest Income Expense | $14,000 | $36,000 | $33,000 | $3,000 |
| Operating Expense | $11,992,000 | $15,843,000 | $13,901,000 | $10,443,000 |
| General And Administrative Expense | $4,697,000 | $4,235,000 | $4,736,000 | $4,533,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Net Interest Income | $14,000 | $36,000 | $33,000 | $3,000 |
| Interest Income | $14,000 | $36,000 | $33,000 | $3,000 |
| Normalized Income | $-11,978,000 | $-15,807,000 | $-13,868,000 | $-10,440,000 |
| Net Income From Continuing And Discontinued Operation | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Total Operating Income As Reported | $-11,992,000 | $-15,843,000 | $-13,901,000 | $-10,443,000 |
| Net Income Common Stockholders | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Net Income | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Net Income Including Noncontrolling Interests | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Net Income Continuous Operations | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Pretax Income | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Interest Income Non Operating | $14,000 | $36,000 | $33,000 | $3,000 |
| Operating Income | $-11,992,000 | $-15,843,000 | $-13,901,000 | $-10,443,000 |
| Per Share | ||||
| Diluted EPS | $-4.12 | $-33.63 | $-38.12 | $-31.00 |
| Basic EPS | $-4.12 | $-33.63 | $-38.12 | $-31.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,917,000 | $-15,394,000 | $-13,723,000 | $-10,282,000 |
| Total Unusual Items | $2,084,000 | $-271,000 | - | - |
| Total Unusual Items Excluding Goodwill | $2,084,000 | $-271,000 | - | - |
| Reconciled Depreciation | $159,000 | $178,000 | $178,000 | $161,000 |
| EBITDA (Bullshit earnings) | $-11,833,000 | $-15,665,000 | $-13,723,000 | $-10,282,000 |
| EBIT | $-11,992,000 | $-15,843,000 | $-13,901,000 | $-10,443,000 |
| Diluted Average Shares | $2,401,000 | $478,000 | $364,000 | $336,250 |
| Basic Average Shares | $2,401,000 | $478,000 | $364,000 | $336,250 |
| Diluted NI Availto Com Stockholders | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Gain On Sale Of Security | $2,084,000 | $-271,000 | - | - |
| Research And Development | $7,295,000 | $11,608,000 | $9,165,000 | $5,910,000 |
| Selling General And Administration | $4,697,000 | $4,235,000 | $4,736,000 | $4,533,000 |
| Other Gand A | $4,697,000 | $4,235,000 | $4,736,000 | $4,533,000 |
| Salaries And Wages | - | - | $655,000 | $655,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $154,000 | $441,000 | $14,174,000 | $25,457,000 |
| Total Assets | $3,883,000 | $3,220,000 | $15,971,000 | $26,568,000 |
| Total Non Current Assets | $107,000 | $178,000 | $356,000 | $428,000 |
| Current Assets | $3,776,000 | $3,042,000 | $15,615,000 | $26,140,000 |
| Prepaid Assets | $2,603,000 | $1,990,000 | $5,231,000 | $2,366,000 |
| Cash Cash Equivalents And Short Term Investments | $1,173,000 | $1,052,000 | $10,384,000 | $23,774,000 |
| Cash And Cash Equivalents | $1,173,000 | $1,052,000 | $10,384,000 | $23,774,000 |
| Cash Financial | $1,173,000 | $1,052,000 | $10,384,000 | $23,774,000 |
| Debt | ||||
| Total Debt | $83,000 | $113,000 | $221,000 | $235,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $10,000 | $113,000 | $153,000 |
| Current Debt And Capital Lease Obligation | $83,000 | $103,000 | $108,000 | $82,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,729,000 | $2,779,000 | $1,797,000 | $1,111,000 |
| Total Non Current Liabilities Net Minority Interest | $434,000 | $873,000 | $113,000 | $153,000 |
| Derivative Product Liabilities | $434,000 | $863,000 | $0 | - |
| Current Liabilities | $3,295,000 | $1,906,000 | $1,684,000 | $958,000 |
| Payables And Accrued Expenses | $3,212,000 | $1,803,000 | $1,576,000 | $876,000 |
| Payables | $1,274,000 | $457,000 | $667,000 | $106,000 |
| Accounts Payable | $1,274,000 | $457,000 | $667,000 | $106,000 |
| Equity | ||||
| Common Stock Equity | $154,000 | $441,000 | $14,174,000 | $25,457,000 |
| Total Equity Gross Minority Interest | $154,000 | $441,000 | $14,174,000 | $25,457,000 |
| Stockholders Equity | $154,000 | $441,000 | $14,174,000 | $25,457,000 |
| Retained Earnings | $-117,501,000 | $-107,607,000 | $-91,529,000 | $-77,661,000 |
| Other | ||||
| Ordinary Shares Number | $5,767,892 | $617,633 | $398,000 | $358,000 |
| Share Issued | $5,767,892 | $617,633 | $398,000 | $358,000 |
| Tangible Book Value | $154,000 | $441,000 | $14,174,000 | $25,457,000 |
| Invested Capital | $154,000 | $441,000 | $14,174,000 | $25,457,000 |
| Working Capital | $481,000 | $1,136,000 | $13,931,000 | $25,182,000 |
| Capital Lease Obligations | $83,000 | $113,000 | $221,000 | $235,000 |
| Total Capitalization | $154,000 | $441,000 | $14,174,000 | $25,457,000 |
| Additional Paid In Capital | $117,649,000 | $108,047,000 | $105,702,000 | $103,111,000 |
| Capital Stock | $6,000 | $1,000 | $1,000 | $7,000 |
| Common Stock | $6,000 | $1,000 | $1,000 | $7,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $10,000 | $113,000 | $153,000 |
| Current Capital Lease Obligation | $83,000 | $103,000 | $108,000 | $82,000 |
| Current Accrued Expenses | $1,938,000 | $1,346,000 | $909,000 | $770,000 |
| Net PPE | $107,000 | $178,000 | $356,000 | $428,000 |
| Accumulated Depreciation | $-1,054,000 | $-1,044,000 | $-962,000 | $-874,000 |
| Gross PPE | $1,161,000 | $1,222,000 | $1,318,000 | $1,302,000 |
| Leases | $463,000 | $463,000 | $463,000 | $463,000 |
| Other Properties | $565,000 | $583,000 | $679,000 | $663,000 |
| Machinery Furniture Equipment | $133,000 | $176,000 | $176,000 | $176,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | $0 | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,575,000 | $-11,535,000 | $-15,124,000 | $-9,987,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,575,000 | $-11,535,000 | $-15,103,000 | $-9,917,000 |
| Cash Flow From Continuing Operating Activities | $-10,575,000 | $-11,535,000 | $-15,103,000 | $-9,917,000 |
| Operating Gains Losses | $-2,084,000 | $271,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $-21,000 | $-70,000 |
| Cash Flow From Continuing Investing Activities | - | $0 | $-21,000 | $-70,000 |
| Capital Expenditure | - | - | $-21,000 | $-70,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,696,000 | $1,677,000 | $1,734,000 | $15,849,000 |
| Financing Cash Flow | $10,696,000 | $2,203,000 | $1,734,000 | $20,006,000 |
| Cash Flow From Continuing Financing Activities | $10,696,000 | $2,203,000 | $1,734,000 | $20,006,000 |
| Net Common Stock Issuance | $10,696,000 | $1,677,000 | $1,734,000 | $15,849,000 |
| Common Stock Issuance | $10,696,000 | $1,677,000 | $1,734,000 | $15,849,000 |
| Other | ||||
| End Cash Position | $1,173,000 | $1,052,000 | $10,384,000 | $23,774,000 |
| Beginning Cash Position | $1,052,000 | $10,384,000 | $23,774,000 | $13,755,000 |
| Changes In Cash | $121,000 | $-9,332,000 | $-13,390,000 | $10,019,000 |
| Proceeds From Stock Option Exercised | $0 | $526,000 | $0 | $4,157,000 |
| Change In Working Capital | $678,000 | $3,360,000 | $-2,264,000 | $-459,000 |
| Change In Other Current Liabilities | $-118,000 | $-108,000 | $-99,000 | $-95,000 |
| Change In Other Current Assets | $-171,000 | $286,000 | $199,000 | $-915,000 |
| Change In Payables And Accrued Expense | $1,409,000 | $227,000 | $700,000 | $-199,000 |
| Change In Prepaid Assets | $-442,000 | $2,955,000 | $-3,064,000 | $750,000 |
| Stock Based Compensation | $566,000 | $734,000 | $851,000 | $821,000 |
| Depreciation Amortization Depletion | $159,000 | $178,000 | $178,000 | $161,000 |
| Depreciation And Amortization | $159,000 | $178,000 | $178,000 | $161,000 |
| Depreciation | $159,000 | $178,000 | $178,000 | $161,000 |
| Gain Loss On Investment Securities | $-2,084,000 | $271,000 | - | - |
| Net Income From Continuing Operations | $-9,894,000 | $-16,078,000 | $-13,868,000 | $-10,440,000 |
| Net PPE Purchase And Sale | - | $0 | $-21,000 | $-70,000 |
| Purchase Of PPE | - | $0 | $-21,000 | $-70,000 |
Fetched: 2026-02-02